These products are not FDA-approved for safety or efficacy, and aggressive marketing risks blurring the line between access and exploitation
Conversely, meta-analyses generally did not demonstrate systematic differences between diabetic patients and normal glucose-tolerant subjects in GIP [109] and GLP-1 [110] secretion after a meal
Serious risks include pancreatitis, gallbladder disease, and potential for triggering restrictive eating patterns in individuals with eating disorders
And so I think that is why a lot of our employers are interested in in this particular strategy to, again, have guardrails, have some cost containment around these products because the unmitigated use is just not sustainable in terms of a cost and budget impact
Are open to using medication as part of a comprehensive plan, not as a quick fix
J., Cho, B., Jung, H., Choi, H